Dr. Moran Dvela-Levitt

Email
dvelamo@gmail.com
Office
Institute of Nanotechnology and Advanced Materials, Building 206, 4th floor, Rooms C-467 (office); C-468 (lab)
    Research

    Fighting traffic

     

    Protein trafficking is an essential process required for the health and proper functioning of all cells, tissues and systems of the human body. Dysfunction of the trafficking machinery leads to cellular traffic jams, a hallmark of many devastating diseases, such as diabetes, cancer, Alzheimer’s disease, cystic fibrosis and more.

     

    Our lab studies the extensive and highly regulated protein trafficking network and addressing major enigmas in the field such as:

    1. How are billions of proteins shuttled from their site of origin to their final destination?
    2. How is the system regulated to ensure proper recognition and elimination of defective proteins?
    3. How do these pathways go awry in human diseases?
    4. And finally, how can we fix these defective pathways?

     

    Using state-of-the-art imaging technology, the lab conducts high content screening (through genetic CRISPR manipulations, pharmacological perturbations, small molecule libraries, etc.) in complex biological systems, including: mammalian cells, 3D cultures, organoids and mouse models. Our aim is to better understand basic protein trafficking processes and develop therapeutic strategies to combat diseases that result from trafficking malfunction.

    Publications

    1.      Wieder N, Fried JC, Kim C, Sidhom EH, Brown MR, Marshall JL, Arevalo C, Dvela-Levitt M, Kost-Alimova M, Sieber J, Gabriel KR, Pacheco J, Clish C, Abbasi HS, Singh S, Rutter JC, Therrien M, Yoon H, Lai ZW, Baublis A, Subramanian R, Devkota R, Small J, Sreekanth V, Han M, Lim D, Carpenter AE, Flannick J, Finucane H, Haigis MC, Claussnitzer M, Sheu E, Stevens B, Wagner BK, Choudhary A, Shaw JL, Pablo JL, Greka A. (2023)
    FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity.

    Cell Metab.35(5):887-905

    https://pubmed.ncbi.nlm.nih.gov/37075753/

    2.      Dvela-Levitt M. (2021)

    Feed the Flames. Stories in Molecular Medicine.

    Trends in Molecular Medicine. 27(4):293-296

    https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(21)00043-5#.YEfspfBBv28.twitter

    3.      Dvela-Levitt M, Shaw LJ, and Greka A. (2021)

    A rare kidney disease to cure them all? Towards mechanism-based therapies for proteinopathies.

    Trends in Molecular Medicine. 16;S1471-4914(20)30312-9

    https://pubmed.ncbi.nlm.nih.gov/33341352/

    4.      Alimova M, Sidhom E, Satyam A, Dvela-Levitt M, Melanson M, Chamberlain1 BT, Alper SL, Santos J, Gutierrez J, Subramanian A, Grinkevich E, Bricio ER, KimC, Clark A, Watts A, Thompson R, Marshall J, Pablo JL, Coraor J, Roignot J, Vernon KA, Keller K, Campbell A, Emani M, Racette M, Bazua-Valenti S, Padovano V, Weins A, McAdoo SP, Tam F, Ronco L, Wagner F, Tsokos GC, Shaw JL, Greka. (2020)

    A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

    Cell Reports Medicine 1 (8)

    https://www.sciencedirect.com/science/article/pii/S2666379120301816

    5.       Dvela-Levitt M, Kost-Alimova M, Emani M, Kohnert E, Thompson R, Sidhom EH, Rivadeneira A, Sahakian N, Roignot J, Papagregoriou G, Montesinos MS, Clark AR, McKinney D, Gutierrez J, Roth M, Ronco L, Elonga E, Carter T, Gnirke A, Melanson M, Hartland K, Wieder N, Hsu JCH, Deltas C, Hughey R, Bleyer AJ, Kmoch S, Živná M, Barešova V, Kota S, Schlondorff J, Heiman M, Alper SL, Wagner F, Weins A, Golub TR, Lander ES, Greka A. (2019)

    Small molecule targets TMED9 and promotes lysosomal degradation to reverse proteinopathy.

    Cell. 178(3):521-535.

    https://www.sciencedirect.com/science/article/pii/S009286741930741X?dgcid=coauthor

    6.       Zhou Y, Castonguay P, Sidhom EH, Clark AR, Dvela-Levitt M, Kim S, Sieber J, Wieder N, Jung JY, Andreeva S, Reichardt J, Dubois F, Hoffmann SC, Basgen JM, Montesinos MS, Weins A, Johnson AC, Lander ES, Garrett MR, Hopkins CR, Greka A. (2017)

    A small-molecule inhibitor of TRPC5 ion channels suppresses progressive kidney disease in animal models.

    Science. 8;358(6368):1332-1336.

    https://www.ncbi.nlm.nih.gov/pubmed/29217578

    7.       Sieber J, Wieder N, Ostrosky-Frid M, Dvela-Levitt M, Aygün O, Udeshi ND, Carr SA, Greka A. (2017)

    Lysine trimethylation regulates 78-kDa glucose-regulated protein proteostasis during endoplasmic reticulum stress. 

    J Biol Chem. 17;292(46):18878-18885.

    https://www.ncbi.nlm.nih.gov/pubmed/28912266

    8.       Dvela-Levitt M, Cohen-Ben Ami H, Rosen H, Ornoy A, Hochner-Celnikier D, Granat M and Lichtstein D. (2015)

    Reduction in maternal circulating ouabain impairs offspring growth and kidney development.

    J. Am. Soc. Nephrol. 26(5):1103-1.

    http://www.ncbi.nlm.nih.gov/pubmed/25294233

    9.       Dvela-Levitt M, Cohen-Ben Ami H, Rosen H, Shohami E and Lichtstein D. (2014)

    Ouabain improves functional recovery following traumatic brain injury.

    J Neurotrauma. 1;31(23):1942-7.

    http://www.ncbi.nlm.nih.gov/pubmed/25007121

    10.    Lichtstein D, Rosen H and Dvela M. (2012)

    Cardenolides and bufadienolides as hormones: What is missing?

    Am. J. Physiol. Renal Physiol. 302(8):F957-8. *Commentary

           http://www.ncbi.nlm.nih.gov/pubmed/22301627

    11.    Dvela M, Rosen H, Cohen-Ben Ami H and Lichtstein D. (2012)

    Endogenous ouabain regulates cell viability.

    Am J Physiol Cell Physiol. 302(2):C442-52.

    http://www.ncbi.nlm.nih.gov/pubmed/22031604

    12.    Jaiswal M, Dvela M, Lichtstein D and Mallick B. (2010)

    Endogenous Ouabain-Like Compounds in Locus Coeruleus Modulate Rapid Eye Movement Sleep in Rats.

    J. Sleep Res. 19(1 Pt 2):183-91.

           http://www.ncbi.nlm.nih.gov/pubmed/19878449

    13.    Nesher M, Shpolansky U, Viola N, Dvela M, Buzaglo N, Cohen Ben-Ami H, Rosen H and Lichtstein D. (2010)

    Ouabain attenuates cardiotoxicity induced by other cardiac steroids.

    Br. J. Pharmacol. 160(2):346-54.

           http://www.ncbi.nlm.nih.gov/pubmed/20423344

    14.    Nesher M, Dvela M, Igbokwe VU, Rosen H, and Lichtstein D. (2009)

    Physiological roles of endogenous ouabain in normal rat. 

    Am. J. Physiol. Heart Circ Physiol. 297(6):H2026-34.

           http://www.ncbi.nlm.nih.gov/pubmed/19837951

    15.    Dvela M, Rosen H, Feldmann T, Nesher M and Lichtstein D. (2007)

    Diverse biological responses to different cardiotonic steroids.

    Pathophysiology. 14: 159-66. *Review article

           http://www.ncbi.nlm.nih.gov/pubmed/17964766

     

    Last Updated Date : 03/03/2025